Finding Aid to the Charles Savage Papers, 1940-2003

Total Page:16

File Type:pdf, Size:1020Kb

Load more

FINDING AID TO THE CHARLES SAVAGE PAPERS, 1940-2003 Purdue University Libraries Virginia Kelly Karnes Archives and Special Collections Research Center 504 West State Street West Lafayette, Indiana 47907-2058 (765) 494-2839 http://www.lib.purdue.edu/spcol © 2012 Purdue University Libraries. All rights reserved. Updated by: Stephanie Schmitz, June 2014 Processed by: Kristin Leaman, July 22, 2013 Descriptive Summary Creator Information Savage, Charles Title Charles Savage papers Collection Identifier MSP 70 Date Span 1940-2003, predominant 1960-1970 Abstract The Charles Savage papers documents his professional and personal life focusing on his research concerning the therapeutic use of LSD and marijuana, his stay and research in West Africa, and his involvement with Spring Grove State Hospital, Maryland Psychiatric Research Center, and Friends of Psychiatric Research. The collection contains personal manuscripts, articles, grant applications, patient notes, and correspondence. Extent 7 cubic feet (14 mss boxes) Finding Aid Author Kristin Leaman, 2013 Languages English Repository Virginia Kelly Karnes Archives and Special Collections Research Center, Purdue University Libraries Administrative Information Location Information: ASC Access Restrictions: Collection is open for research; however, portions of the collection are restricted to protect the privacy of patients. Papers from the collection containing patient names and other personal information are restricted for seventy-five years from the date of their creation. Redacted photocopies of this material has been put in place of the originals. Acquisition Donated by Emmy Savage, August 8, 2009; February Information: 20, 2011; April 27, 2011; May 2, 2011. 7/2/2014 2 Accession Number: 20090819 20110220 20110427 20110502 Preferred Citation: MSP 70, Charles Savage papers, Archives and Special Collections, Purdue University Libraries Copyright Notice: Copyright restrictions may apply. Consult an archivist for details. Subjects and Genres Persons Savage, Charles Organizations Maryland State Psychiatric Research Center Spring Grove Hospital Center (Md.) Veterans Administration Hospital (Baltimore, MD) Washington-Baltimore Psychoanalytic Society Washington Psychiatric Society (Washington, D. C.) Topics LSD (Drug)—Therapeutic Use Marijuana—Therapeutic Use Research grants Yoruba (African people) Form and Genre Types Articles Correspondence Grant proposals Reports Reprints Occupations Psychology Psychiatry Psychotherapy 7/2/2014 3 Biography of Charles Savage Charles W. Savage was born on September 25, 1918 in Berlin, Connecticut. He received a B.A. from Yale in 1939, an M.D. from the University of Chicago in 1945, and an M.A. in Spanish from Middlebury College in 1999. He also attended the Washington-Baltimore Psychoanalytic Institute in 1957 and served as a Lieutenant Mass Communication Specialist in the United States Navy from 1946-1953. He published fifty papers on psychopharmacology and psychoanalysis, several of which were co-authored with his wife, Ethel. He was a member of the editorial board of Psychiatry and a member of the American Psychiatric Association (fellow), American Psychoanalytic Association, American Electoencephlogram Society, American Association for the Advancement of Science, Washington Psychoanalytic Society, Baltimore Psychoanalytic Society, San Francisco Psychoanalytic Society. Savage was also a poet and published, in Spanish and English, Las Tinieblas en el Dia de Pentecostes. Upon his retirement, he became a medical missionary to Guatemala. At the age of 89, Savage passed away at his home on December 12, 2007. Chronology 1945 Intern at the University of Chicago, Chicago, Illinois 1946 Assistant resident in psychiatry at Yale University, New Haven, Connecticut 1947-1948 Resident psychiatrist at the U.S. Naval Hospital, Bethesda, Maryland 1948-1949 Chief psychiatrist at the U. S. Naval Hospital, Charleston, South Carolina 1949-1952 Research Psychiatrist at the Naval Medical Research Institute and the National Naval Medical Center, both Bethesda, Maryland 1951 Diplomat of American Board of Psychiatry and Neurology 1957-1958 Fellow of Center for Advanced Study in the Behavioral Sciences, Stanford, California 7/2/2014 4 1953-1958 Acting chief adult psychiatrist at the National Institute of Mental Health, Bethesda, Maryland 1958-1960 Psychiatrist at the Livermore Sanitarium, Livermore, California 1961 Research associate on Aro Project at Abeo Kuta, Nigeria at Cornell University, Ithaca, New York 1961-1962 Psychiatrist at the Stanford Veterans Administration Hospital, Palo Alto, California 1962-1964 Medical director at the International Foundation for Advanced Study, Menlo Park, California 1964-1965 Psychiatrist, County of Santa Clara, San Jose, California 1965 Assistant professor at Johns Hopkins University 1967 David C. Wilson Society Lecturer at University of Virginia 1965-1968 Clinical assistant professor at the University of Maryland 1965-1968 Director of research at the Spring Grove State Hospital, Baltimore, Maryland 1968-1972 Associate Director and Research Scientist at the Maryland Psychiatric Research Center, Baltimore, Maryland 1968-1972 Clinical associate professor at the University of Maryland 1972 Chief of psychiatric services and chief of Drug Treatment Center at the Veterans Administration Hospital, Baltimore, Maryland 7/2/2014 5 1972 Associate Professor at the University of Maryland Sources: “Charles Savage.” Contemporary Authors Online. Detroit: Gale, 2002. Gale Biography in Context. Web. 12 September 2012. “Charles Savage.” American Men & Women of Science: A Biographical Directory of Today’s Leaders in Physical, Biological, and Related Sciences. Detroit: Gale, 2008. Gale Biography In Context. Web. 12 September 2012. Obituary of Charles Savage, The Washington Post (Washington, D. C.), December 20, 2007. 7/2/2014 6 Collection Description Scope The Charles Savage papers (1936-2003; 7 cubic feet) document Savage’s work as a psychiatrist, specifically his research on the therapeutic use of LSD-25 and marijuana during the 1960s. Materials range from correspondence between Savage and his colleagues and Savage and his patients, article reprints written by Savage or used by Savage for his research, as well as Savage’s manuscripts and miscellaneous manuscripts, some of which appear to have been created by patients. Patient notes, accounts and transcripts of LSD sessions, and information on the Spring Grove Hospital and the Maryland State Psychiatric Research Center are all included. This collection also documents Savage’s time in the Navy, as well as activities subsequent to his retirement. Arrangement The Charles Savage papers have been arranged in nine series. 1. Biographical Information, 1940-1984 (0.5 cubic feet). Series 1 contains Savage’s Navy orders, certifications, conference materials, curriculum vitae, and other biographical information and materials. 2. Correspondence, 1936-2001 (1.5 cubic feet). Series 2 contains correspondence between Savage and his colleagues and patients, miscellaneous and undated correspondence, memorandums, and reading files. Boxes 2 and 3 are in Savage’s original order. 3. Article Reprints and Reviews, 1949-2003 (0.5 cubic feet). Series 3 contains dated and undated article reprints that Savage used for research, as well as his article reviews. Some of the article reprints are written by him, or they are articles he may have reviewed. The materials are arranged chronologically. 4. Article, Report, and Presentation manuscripts, 1946-1980, undated (1 cubic foot). Series 4 contains manuscripts and undated manuscripts documenting Savage’s research, as well as miscellaneous manuscripts possibly created by Savage, his patients, or his colleagues. Materials are arranged chronologically when possible. Undated materials are arranged alphabetically by the author’s last name. 5. Research and Grant materials, 1962-1979 (0.25 cubic feet). Series 5 contains grant applications and research completed by Savage and his colleagues. 6. Washington Psychoanalytic Society, 1947-2000 (0.25 cubic feet). Series 6 contains information concerning Savage’s involvement in the Washington Psychoanalytic Society, a nonprofit organization affiliated with the American Psychoanalytic Association that offered training and practice in the theory of 7/2/2014 7 psychoanalysis. This series contains correspondence between Savage and board members of this organization (arranged chronologically), an oral history transcript detailing Savage’s relation with the organizations, and newsletters, memorandums, meeting minutes and agendas generated by the organization. 7. LSD Research materials, 1960-1969 (0.5 cubic feet). Series 7 contains Savage’s research, patient information, correspondence, and other materials pertaining to LSD research. 8. Spring Grove State Hospital materials, 1962-1969 (0.25 cubic feet). Series 8 contains plans and procedures for psychedelic research at Spring Grove State Hospital, as well as correspondence, reports, patient notes and monthly reports detailing the activities there. 9. Marijuana Research materials, 1971-1975 (0.1 cubic feet). Series 9 contains correspondence, reports, papers, and other materials pertaining to marijuana studies. 10. Maryland Psychiatric Research Center and Friends of Psychiatric Research, 1967-1969 (0.15 cubic feet). Series 10 contains correspondence, papers, reports, and other materials relating to Savage’s involvement with the Maryland Psychiatric Research Center and Friends of Psychiatric Research. Friends
Recommended publications
  • Cerebellar Toxicity of Phencyclidine

    Cerebellar Toxicity of Phencyclidine

    The Journal of Neuroscience, March 1995, 75(3): 2097-2108 Cerebellar Toxicity of Phencyclidine Riitta N&kki, Jari Koistinaho, Frank Ft. Sharp, and Stephen M. Sagar Department of Neurology, University of California, and Veterans Affairs Medical Center, San Francisco, California 94121 Phencyclidine (PCP), clizocilpine maleate (MK801), and oth- Phencyclidine (PCP), dizocilpine maleate (MK801), and other er NMDA antagonists are toxic to neurons in the posterior NMDA receptor antagonistshave attracted increasing attention cingulate and retrosplenial cortex. To determine if addition- becauseof their therapeutic potential. These drugs have neuro- al neurons are damaged, the distribution of microglial ac- protective properties in animal studies of focal brain ischemia, tivation and 70 kDa heat shock protein (HSP70) induction where excitotoxicity is proposedto be an important mechanism was studied following the administration of PCP and of neuronal cell death (Dalkara et al., 1990; Martinez-Arizala et MK801 to rats. PCP (10-50 mg/kg) induced microglial ac- al., 1990). Moreover, NMDA antagonists decrease neuronal tivation and neuronal HSP70 mRNA and protein expression damage and dysfunction in other pathological conditions, in- in the posterior cingulate and retrosplenial cortex. In ad- cluding hypoglycemia (Nellgard and Wieloch, 1992) and pro- dition, coronal sections of the cerebellar vermis of PCP (50 longed seizures(Church and Lodge, 1990; Faingold et al., 1993). mg/kg) treated rats contained vertical stripes of activated However, NMDA antagonists are toxic to certain neuronal microglial in the molecular layer. In the sagittal plane, the populations in the brain. Olney et al. (1989) demonstratedthat microglial activation occurred in irregularly shaped patch- the noncompetitive NMDA antagonists,PCP, MK801, and ke- es, suggesting damage to Purkinje cells.
  • Self-Administration of Abused Substances: Methods for Study

    Self-Administration of Abused Substances: Methods for Study

    Self-Administration of Abused Substances: Methods for Study U.S. DEPARTMENT OF HEALTH, EDUCATION AND WELFARE Public Health Service Alcohol, Drug Abuse, and Mental Health Administration Self-Administration of Abused Substances: Methods for Study Editor: Norman A. Krasnegor, Ph.D. NIDA Research Monograph 20 July 1978 DEPARTMENT OF HEALTH. EDUCATION, AND WELFARE Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents U.S. Government Printing Office, Washington, D.C. 20402 Stock No. 017-024-00794-3 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical re- views of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Polo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Department of Psychology. UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHEW Washington, D C Lee Robins, Ph.D. Washington University School of Medicine St Louis, Missouri NIDA Research Monograph series William Pollin, M.D.
  • Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence

    Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence

    National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1980 Proceedings of the 42nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1980 Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 34 February 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Deportment of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C Lee Robins, Ph.D.
  • DEMAND REDUCTION a Glossary of Terms

    DEMAND REDUCTION a Glossary of Terms

    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
  • Pharmacological Profile of Dizocilpine (Mk-801) And€Its

    Pharmacological Profile of Dizocilpine (Mk-801) And€Its

    Mil. Med. Sci. Lett. (Voj. Zdrav. Listy) 2019, 88(4), 166-179 ISSN 0372-7025 (Print) ISSN 2571-113X (Online) DOI: 10.31482/mmsl.2019.019 Since 1925 PŘEHLEDOVÝ ČLÁNEK / REVIEW ARTICLE FARMAKOLOGICKÝ PROFIL DIZOCILPINU (MK-801) A MOŽNOSTI JEHO VYUŽITÍ VE ZVÍŘECÍCH MODELECH SCHIZOFRENIE PHARMACOLOGICAL PROFILE OF DIZOCILPINE (MK-801) AND ITS POTENTIAL USE IN ANIMAL MODEL OF SCHIZOPHRENIA Jan Konečný 1,2, Radomír Jůza 3, Ondřej Soukup 1,2, Jan Korábečný 1,2,3 1 Katedra toxikologie a vojenské farmacie, Fakulta vojenského zdravotnictví, Třebešská 1575, 500 02, Hradec Králové, Česká republika 2 Centrum biomedicínského výzkumu, Fakultní nemocnice Hradec Králové, Sokolská 581, 500 05 Hradec Králové, Česká republika 3 Národní ústav duševního zdraví, Topolová 748, 250 67 Klecany, Česká republika Přijato 19. července 2019. Akceptováno 5. září 2019. Zveřejněno 6. prosince 2019. Souhrn N-Methyl-D-aspartátový (NMDA) receptor patří do skupiny glutamátových receptorů, které se dále dělí na ionotropní a metabotropní. V CNS má vliv na synaptickou plasticitu a rozvoj neuronálních synapsí. Ionotropní NMDA receptory jsou aktivovány glutamátem, díky čemuž proudí pozitivně nabité ionty skrz membránu po svém koncentračním gradientu. Nicméně nadměrné hladiny glutamátu působí excitotoxicky díky vysokým intracelulárním hladinám Ca2+ a mohou vést k buněčné smrti neuronů pozorované např. u neurodegenerativních onemocnění. Antagonisté NMDA receptorů, mezi které patří například dizocilpin, ovlivňují prostupnost NMDA receptoru a zamezují tak vstupu iontů Ca2+ do buňky. Dizocilpin působí jako nekompetitivní antagonista NMDA receptoru, má antikonvulzivní a anestetické účinky. Jeho terapeutické použití u lidí není vhodné z důvodu výskytu četných vedlejších účinků, experimentálně je však využíván jako farmakologicky indukovaný animální model schizofrenie.
  • Phencyclidine: an Update

    Phencyclidine: an Update

    Phencyclidine: An Update U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse and Mental Health Administration Phencyclidine: An Update Editor: Doris H. Clouet, Ph.D. Division of Preclinical Research National Institute on Drug Abuse and New York State Division of Substance Abuse Services NIDA Research Monograph 64 1986 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administratlon National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20657 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National lnstitute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY COHEN, M.D. Temple University School of Medicine Los Angeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic lnstitute National Federation of Parents for Troy, New York Drug Free Youth RICHARD E. BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTEMAN Langley Porter Neuropsychiatric lnstitute Alcohol and Drug Problems Association San Francisco, California of North America Washington, D.C. DENISE KANDEL, Ph.D GILBERT J. BOTV N, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
  • (Ph OH N N Me O YO O YO

    (Ph OH N N Me O YO O YO

    US 20070265293A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0265293 A1 Boyd et al. (43) Pub. Date: Nov. 15, 2007 (54) (S)-N-METHYLNALTREXONE Publication Classification (76) Inventors: Thomas A. Boyd, Grandview, NY (51) Int. Cl. (US); Howard Wagoner, Warwick, NY A6II 3L/4355 (2006.01) (US); Suketu P. Sanghvi, Kendall Park, A6M II/00 (2006.01) NJ (US); Christopher Verbicky, A6M I5/08 (2006.01) Broadalbin, NY (US); Stephen 39t. 35O C Andruski, Clifton Park, NY (US) (2006.01) A6IP 3L/00 (2006.01) Correspondence Address: St. 4. CR WOLF GREENFIELD & SACKS, P.C. (2006.01) 6OO ATLANTIC AVENUE 3G (i. 308: BOSTON, MA 02210-2206 (US) A6IP 33/02 (2006.01) C07D 489/00 (2006.01) (21) Appl. No.: 11/441,452 (52) U.S. Cl. .............. 514/282; 128/200.23; 128/202.17; (22) Filed: May 25, 2006 546/45 Related U.S. Application Data (57) ABSTRACT This invention relates to S-MNTX, methods of producing (60) Provisional application No. 60/684,570, filed on May S-MNTX, pharmaceutical preparations comprising 25, 2005. S-MNTX and methods for their use. O G M Br Br e (pH OH N N Me O YO O YO OH OH R-MNTX S-MNTX Patent Application Publication Nov. 15, 2007 Sheet 1 of 6 US 2007/0265293 A1 Fig. 1 OH OH Me-N Me-N D / O O -----BBr, O O CHCI NMP, 3 AUTOCLAVE, 70'C OMe OH 1 2 Br OH As GE) G As 69 GOH Me-N ION Me-N -lass O SO EXCHANGE O SO OH OH 3 S-MNTX 1 - OXYCODONE 2 - OXYMORPHONE 3 - ODIDE SALT OF S-MNTX Fig.
  • NIDA Drug Supply Program Catalog, 25Th Edition

    NIDA Drug Supply Program Catalog, 25Th Edition

    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
  • Symposium Iv. Discriminative Stimulus Effects

    Symposium Iv. Discriminative Stimulus Effects

    Life Sciences, Vol. 28, pp. 1571-1584 Pergamon Press Printed in the U.S.A. MINI - SYMPOSIUM IV. DISCRIMINATIVE STIMULUS EFFECTS OF NARCOTICS: EVIDENCE FOR MULTIPLE RECEPTOR-MEDIATED ACTIONS Seymore Herling and James H. Woods Departments of Pharmacology and Psychology University of Michigan Ann Arbor, Michigan q8109 The different pharmacological syndromes produced by morphine and related drugs in the chronic spinal dog led Martin and his colleagues (1,2) to suggest that these drugs exert their agonist actions 0y interacting with three distinct receptors (~,K, and e). Morphine was hypothesized to be an agonist for the p receptor, ketazocine (ketocyclazocine) was an agonist for the K receptor, and SKF-10,0q7 was an agonist for the ~ receptor. The effects of these three drugs in the chronic spinal dog were reversed by the narcotic antagonist, naltrexone, indicating that the effects of these drugs are narcotic agonist effects (I). In additlon to the different effects of these narcotics in the non- dependent chronic spinal dog, the effects of morphine, ketazocine, and SKF-IO,047 in several other behavioral and physiological preparations are consistent with the concept of multiple receptors. For example, while ketazocine and ethylketazocine, like morphine, produce analgesia, these compounds, unlike morphine, do not suppress signs of narcotic abstinence in the morphine-dependent rhesus monkey or morphine-dependent chronic spinal dog (1-5). Further, the characteristics of ketazocine withdrawal and antagonist- precipitated abstinence syndromes, although similar to those of cyclazocine, are quailtativeiy different from those of morphine (1,2). In rhesus monkeys, ketazocine, ethylketazocine, and SKF-10,047 maintain lever pressing at rates comparable to or below those maintained by saline, and well below response rates maintained by codeine or morphine (5,6), suggesting that the former set of drugs have limited reinforcing effect.
  • Etoxadrol-Meta-Isothiocyanate: a Potent, Enantioselective, Electrophilic Affinity Ligand for the Phencyclidine-Binding Site

    Etoxadrol-Meta-Isothiocyanate: a Potent, Enantioselective, Electrophilic Affinity Ligand for the Phencyclidine-Binding Site

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Volume 238, number 2, 369-374 FEB 06377 October 1988 Etoxadrol-meta-isothiocyanate: a potent, enantioselective, electrophilic affinity ligand for the phencyclidine-binding site Andrew Thurkauf, Mariena V. Mattson, Philip N. Huguenin*, Kenner C. Rice and Arthur E. Jacobson Section on Drug Design and Synthesis, Laboratory of Neuroscience, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, IUD 20892, USA Received 17 August 1988 Etoxadrol-mera-isothiocyanate (2S,4S,692-ethyl-2-(3-isothiocyanatophenyl)-2-pi~ridyl)1,3-dioxolane, 4n) has been synthesized and characterized as an irreversible ligand for the phencyclidine (PCP)-binding site. It is the first chiral elec- trophilic affinity ligand for this site to have been described. This affinity ligand is based upon etoxadrol, a 1,3-dioxolane known to have PCP-like effects in vivo and in vitro. Etoxadrol-meta-isothiocyanate was found to be four-five times more potent in vitro than metaphit (1-[1-(3-isothiocyanatophenyl)cyclohexyl]pi~~dine), the only previously known electro- philic affinity ligand for the PCP-binding site. The binding was shown to be highly enantioselective for etoxadrol-meta- isothiocyanate (4a). The 2R,4R,6R-enantiomer of 4a was essentially inactive. The ability of the 2S,4$69enantiomer (4a) to interact with the benzodiazepine, muscarinic, and mu opioid receptor systems was also examined, and it was found not to interact with these receptor systems. It seems likely that 4a will prove to be a valuable tool in the study of structure and function of the PCP-binding site.
  • Sympathomimetic Anesthetics

    Sympathomimetic Anesthetics

    SYMPATHOMIMETIC ANESTHETICS GRAHAM CHEN, SC.D., M.D. A NEW TYPE of general anaesthetic drug has been developed in recent years. These drugs produce surgical anaesthesia without causing depression of respiratory and cardiovascular functions. Slight hypertension and taehycardia usually occur fol- lowing their intravenous administration. Mental confusion, dreaming, and a feel- ing of body dissociation are expressed by some individuals during the recovery period. Two classes of compounds containing a basic amine moiety have been shown to possess such properties: arylcycloalkylamines and 2-(2,2 substituted 1,3 dioxo- lan-4-yl) piperidines. Phencyelidine and ketamine belong to the first category, and dexoxadrol and etoxadrol to the latter. The structures of these drugs are shown in Figure 1. The anaesthetic and some other properties of the two classes of chemi- cals are remarkably similar; they may be considered together insofar as their principal pharmacologic actions are concerned. The purpose of this communication is to describe the neuropharmacological characteristics of these drugs, to indicate structure-activity relationships, and to discuss the mode of their anaesthetic actions. PHARMACOLOGY The progressive central effects of arylcycloalkylamines and 2-(2,2 substituted 1,3 dioxolan-4-yl) piperidines administered to animals in increasing doses gen- erally are excitation, ataxia, catalepsy, general anaesthesia and conwdsions. The degree of stimulation and depression varies with animal species and different compounds. Excitation is a prominent initial effect in rats and mice. It does not usually occur in primates, including man. 1- ~ Ataxia is a concomitant effect in rats and mice, and may occur in other species even in the absence of excitement.1 -3 Catalepsy, similar to that produced by bulbocapnine, is an outstanding central effect of these agents in all species including man.
  • The Joint French-US Seminar on Phencyclidine and Related

    The Joint French-US Seminar on Phencyclidine and Related

    TIPS deptember 1983 363 p-Amin&mmcacid 1 Dihydmplertdtns 1 Dihydmiok acid ’ J Lsym- I I 1 Dit-rfdrotolkacid ) I The joint French-US seminar on Tetrahydroblic acid phencyclidine and related arylcyclohexylamines Protein syllth8sis A joint French-US seminar was held at La (tram OH/N) one of the most potent opioid Grande Motte (Montpellier) France, 20-24 analgesics known. Removal of the oxygen September 1982, to assess the current sci- group in this series produces compounds entific status of phencyclidine (PCP) and with PCP-like activity to varying degrees. related arylcyclohexylamines. The seminar Zimmerman and associates (Lilly) reported L______--:-______I was attended by 58 scientists interested in the discovery and characterization of a new Fig. 5. Flow diagram of purim,thymidine and pro- the chemistry, biochemistry, pharmacol- series of benzo(f)isoquinoline derivatives rein synthesis. ogy, therapeutic applications and drug that have stimulus discriminative properties abuse aspects of arylcyclohexylamines. similar to PCP. One of the most potent is problems presented and the management of Thirty-four American, 19 French, 3 Japan the methylcyclopropyl bridged iso research show important differences, it is ese, 1 British and 1 Israeli investigator quinoline, LY 154045. PCP-like effects essential that industry continues to recruit attended, representing each of the above were maximized with a hydroxyl sub its proper proportion of the available talent. major disciplines. The organizing commit- stituent in the aromatic ring. Medawar has commented that the ordi- tee consisted of E. F. Domino of the Uni- One of the major questions in PCP nary processes of scientific discovery are versity of Michigan and P.